Wockhardt Limited, a pharmaceutical and biotech company, manufactures and trades pharmaceuticals, medicinal, botanical, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. The company develops qualified infectious diseases products comprising WCK5222, which is in phase 3 clinical trial for the treatment of sepsis and hospital/ventilator associated pneumonia; WCK 4282, which is in phase 3 clinical trial for ESBL infections; WCK 6777, which is phase 1 to treat gram negative infections; and WCK 4873, which is phase 3 clinical trial for community-acquired bacterial pneumonia. It also offers rapid and long-acting insulin analogues, concentrated insulins, GLP1 analogues, haemopoietins, biobetters and novel products, and delivery devices. In addition, the company develops and commercializes Biovac-B, a hepatitis B vaccine; WEPOX, a recombinant human erythropoietin; WOSULIN, a recombinant human insulin; and GLARITUS, a recombinant insulin glargine. Further, it provides contract manufacturing services; offers and active pharmaceutical ingredients. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.